comparemela.com

Latest Breaking News On - Numis securities limited joint broker - Page 3 : comparemela.com

Synairgen plc: Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

Analysis of 60 and 90-day data from Phase 3 SPRINTER trial in hospitalised COVID-19 patients showed that SNG001 reduced risk of recognised Long COVID symptoms Company to present full analysis

Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Synairgen plc: Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces positive

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.